Clade Ib mpox cases diagnosed in Kenya from July 2024 to February 2025

A descriptive outbreak report documents the diagnosis of clade Ib mpox cases in Kenya from July 2024 to February 2025. This is a case series without a reported sample size, specific intervention or exposure, comparator group, or primary outcome. The report states only that cases were diagnosed, providing no absolute numbers, effect sizes, p-values, or confidence intervals.

No safety or tolerability data were reported, including adverse events, serious adverse events, or discontinuations. The report does not mention funding sources or potential conflicts of interest.

Key limitations include the purely descriptive nature of the evidence. No comparative analysis was performed, and no causal inferences can be drawn. The practice relevance is not reported, and clinicians should interpret this as surveillance information rather than evidence for clinical decision-making.